Announcements
Coronavirus Disease 2019 (COVID-19) Updates Related to Sponsored Programs
Latest Update: April 16, 2020
Check here for updates regarding how COVID-19 is affecting sponsored programs at the University of Louisiana at Lafayette. Links to resource information from sponsoring agencies and federal regulators is provided below.
If you have any information to share, please e-mail us at spfac@louisiana.edu.
You should reach out to your Post Award Specialist IMMEDIATELY if you have any questions or need assistance with notifying sponsors.
Here are a few simple scenarios in order to consider these impacts:
-
What would the impact be to your research and sponsored programs if you had to self-quarantine for two weeks?
-
What would the impact be to your research and sponsored programs if more than one of your research staff had to self-quarantine for two weeks?
-
What would the impact be to your research and sponsored programs if UL advised all faculty and staff to work remotely?
Here are additional questions to help you assess how an outbreak may affect your research:
-
Are there any studies involving participants, animals, ingredients, or experiments that would be adversely affected? If so, what plans should be put in place to allow for them to continue or allow for them to be stopped and later resumed in the least impactful way?
-
What standing purchase orders or human resource issues might be impacted?
-
Would data collection/analysis/storage be impacted and what costs would be associated with these impacts?
-
What regulatory approvals will expire soon and might be impacted if they are not renewed? Can they be renewed early?
-
Are there any collaborators that would need to be notified?
-
What sponsor reports or deadlines are due during the next several months? Might you need to request a no-cost extension?
-
What notice might you need to give sponsors or regulators if the research is going to be paused or significantly delayed beyond a couple of weeks?
Additional considerations for human subjects research:
-
Is the location of the study remaining open and available for participants to be present? Has the location implemented any procedures to slow the spread of the coronavirus that will affect participation in your study or the ability of your study to proceed?
-
Does your protocol require in-person participation or treatment? Can it be modified for remote participation?
-
Does your protocol require in-person monitoring? Can it be modified for remote monitoring?
-
Should your participants be screened for coronavirus as part of your inclusion/exclusion criteria?
-
Would your data or results be affected if your participants had to self-quarantine or if they contracted coronavirus?
Additional considerations for environmental health and safety:
-
Do you have a limited number of critical lab staff with unique knowledge? Are there others in your lab who can be cross-trained?
-
Does your lab operate machines that use active cooling through liquid gasses, dry boxes, or inert boxes using gas blankets? What would happen if materials like liquid gasses, CO2, nitrogen, or dry ice become unavailable?
-
How frequently are you saving or freezing samples of your cell cultures?
-
Do you have long-term experiments that might benefit from more frequent preservation?
-
Do you have the requisite local knowledge to do controlled shutdowns of complex machines or devices without on-site help from the company?
-
Have you shared with the appropriate UL department the locations and amounts of materials that are air, water, or otherwise unstable for observation in case of lab closure?
Allowability of Costs Related to COVID-19
Am I allowed to pay staff who may be quarantined on sponsored funding?
Federal agencies are working internally on a number of proposal and award-related issues pertaining to COVID-19. We are awaiting further communication from our partners about these issues and will provide guidance as further information becomes available. In the meantime, please continue to follow all relevant policies and procedures and apply those practices consistently. Currently, salary should be charged in a consistent manner. If an employee’s salary is charged to a sponsored program, then their time spent in quarantine can also be charged to the sponsored program.
Are travel costs, which have been canceled due to COVID-19, allowable on sponsored funding?
Federal agencies are working internally on a number of proposal and award-related issues pertaining to COVID-19. We are awaiting further communication from our partners about these issues and will provide guidance as further information becomes available. In the meantime, please continue to follow all relevant policies and procedures and apply those practices consistently. If the original expense was allocable to a sponsored project, the subsequent fees for changing/canceling travel would also be allocable to that project.
Resources
|
TITLE |
DESCRIPTION |
|---|---|
|
This interim guidance from the U.S. Centers for Disease Control and Prevention, intended for institutions of higher education, is based on what is currently known about the transmission and severity of coronavirus disease 2019 (COVID-19). |
|
|
Institutional and Agency Responses to COVID-19 and Additional Resources |
A collection of resources from various institutions of higher education compiled by the Council On Governmental Relations. |
|
ASSISTANT SECRETARY OF THE NAVY FOR RESEARCH, DEVELOPMENT, AND ACQUISITION |
|
|
Memorandum for distribution in regards to engaging the Research and Development Industrial Base during COVID-19 |
|
|
BATTELLE ENERGY ALLIANCE, LLC |
|
|
Controls to limit risk of Coronavirus spread at Battelle Eneregy Alliance, LLC. |
|
|
BOARD OF REGENTS |
|
|
Deadline date for receipt requests to amend contracts and/or revise budgets for all BoRSF contracts and procedure for submitting request. |
|
|
CENTER FOR DISEASE CONTROL |
|
|
Information for CDC applicants and recipients of CDC funding. |
|
|
General funding and grants frequently asked questions. |
|
|
CORPORATION FOR PUBLIC BROADCASTING |
|
|
Message from CPB President and CEO Pat Harrison |
|
|
Message from CPB President and CEO Pat Harrison regarding CSG payments. |
|
|
*Added 04/16/2020 Message from CPB President regarding distribution plan for the FY2020 stabilization funds |
|
|
DEFENSE ADVANCED RESEARCH PROJECTS AGENCY |
|
|
FAQs about COVID-19 for DARPA Performers |
|
|
DEPARTMENT OF EDUCATION |
|
|
Select questions related to use of Departmet of Education grant funds during the novel Coronavirus disease 2019. |
|
|
DEPARTMENT OF ENERGY |
|
| Department of Energy Memo for Applicants and Awardess |
Accommodating interruptions from Coronavirus Disease 2019 |
|
PF 2020-20 COVID-19 Guidance for Financial Assistance Actions |
Policy Flash 2020-20 provides COVID-19 guidance for financial assistance actions. |
|
Notice from DOE regarding ARPA-E actions owing to the COVID-19 public health emergency. |
|
|
DEPARTMENT OF HEALTH & HUAMAN SERVICES |
|
|
Preparation for Potential COVID-19 Impact on Contract and Contractor Performace |
|
|
DEPARTMENT OF INTERIOR |
|
|
COVID-19 updated for financial assistance recipients |
|
|
DEPARTMENT OF THE AIR FORCE |
|
|
Potential Contract Impacts due to COVID-19. |
|
|
Guidance fo COVIID-19 no cost extensions |
|
|
DEPARTMENT OF TRANSPORTATION |
|
|
U.S. Department of Transportation announces deadline extension for federal transit administration competitive grant programs |
|
|
ENVIRONMENTAL PROTECTION AGENCY |
|
|
EPA frequent questions on grants issues in response to the novel Coronavirus (COVID-19) public health emergency |
|
|
INSTITUE OF MUSEUM AND LIBRARY SERVICES |
|
|
FAQs for IMLS grant applicants and awardees with questions about the impact of COVID-19 on their IMLS-related work |
|
|
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION |
|
|
Updates and resources regarding COVID-19 from NASA |
|
|
COVID-19 Impact to NASA SBIR/STTR Program |
|
|
NASA memo to contractors: Preserviing readiness of the space industrial base and mission operational readiness due to the COVID-19 situation. |
|
|
NASA FAQs regarding Grants and Research during the COVID-19 Epidemic |
|
| NASA Implementation of OMB Memorandum M-20-17 | |
|
NATIONAL ENDOWMENT FOR THE ARTS |
|
|
National Endowment for the Arts FAQs and information for applicants and grantees in response to COVID-19 |
|
|
NATIONAL ENDOWNMENT FOR THE HUMANITIES |
|
|
FAQs - Funding for NEH applicants and grantees impacted by the Cornoavirus |
|
|
NATIONAL INSTITUTES OF HEALTH |
|
|
Guidance for NIH-funded Clinical Trials and Human Subjects Studies Affected by COVID-19 |
Provide guidance outlining the flexibilities available to recipients conducting NIH-funded clinical trials and human subject studies impacted by COVID-19 |
|
Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients |
Guidance and resources compiled by NIH. |
|
NIH FAQs on Proposal Submission and Award Management Related to COVID-19 |
|
|
NIH information including NIH guidance on travel and meetings. |
|
|
NIH Extramural Response to Natural Disasters and Other Emergencies |
NIH policies on natural disasters and other emergencies. |
|
NIH special provisions implemented in response to COVID-19. (Issued March 9) |
|
|
Flexibilities for Assured Institutions for Activities of IACUCs Due to COVID-19 (March 16) |
Flexibilities for Assured Institutions for Activities of Institutional Animal Care and Use Committees (IACUCs) Due to COVID-19 (Issued March 16) |
|
NIH Late Application Policy Due to Public Health Emergency for United States for 2019 Novel Coronavirus (COVID-19). (Issued March 26) |
|
|
NATIONAL SCIENCE FOUNDATION |
|
|
National Science Foundation Statement on Coronavirus Disease 2019 (COVID-19) |
NSF actions in response to COVID-19. |
|
Frequently Asked Questions (FAQs) About the Coronavirus Disease 2019 (COVID-19) for National Science Foundation (NSF) Proposers and Awardees. |
|
|
Frequently Asked Questions (FAQs) About the Coronavirus Disease 2019 (COVID-19) for National Science Foundation (NSF) Proposers and Awardees. (Updated 04/02/2020) |
|
|
NSF’s Dear Colleague Letter with information regarding the RAPID funding mechanism as it relates to COVID-19. |
|
|
NSF Implementation of OMB Memorandum M-20-17 dated March 19,2020 (Revised April 01,2020) |
|
|
Impact on Existing Deadline Dates for proposers. |
|
|
NSF letter to Chemistry community regarding loss of operations, future manufacturing webinar, QIS international supplements, RFI Covergence accelerator, S-STEM as it related to COVID-19. |
|
|
Frequently asked questions regarding the NSF Dear Colleauge Letter (DCL) on the Coronavirus Disease 2019 |
|
|
*Added 04/16/2020 Frequently asked questions about the Coronavirus for Research Experience for Undergraduates Sites, Research Experiences for Teacher Sies, International Research Experiecne for Students Sites, and similar activities |
|
|
*Added 04/16/2020 NSF message in regards to costs to major facilities during COVID-19 |
|
|
MELLON FOUNDATION |
|
| The Mellon Foundation’s communication regarding work interruptions due to COVID-19. | |
|
OFFICE OF JUSTICE PROGRAMS |
|
|
Office of Justice Programs guidance sent to grantees regarding COVID-19 impact. |
|
|
OFFICE OF MANAGEMENT AND BUDGET |
|
|
Managing federal contract performance issues associated with the novel Coronoavirus (COVID-19). |
|
|
Administrative relief for recipients and applicants of federal financial assistance direclty impacted by the novel Coronavirus (COVID-19) due to loss of operations. |
|
|
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION |
|
|
COVID-19 information for SAMHSA discretionary grant recipients. |
|
|
Frequently asked questions (FAQs) related to COVID-19 for SAMHSA grant recipients |
|
|
UNITED STATES ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY |
|
|
USAMRAA addresses general questions associated with proposal submission and award management that may arise in relation to COVID-19. |
|
|
USAMRAA's Supplemental Guidance for Grants and Cooperative Agreements |
USAMRAA's Supplement Guidance on administrative flexibilities for Grants and Cooperative Agreements in response to COVID-19 pandemic. |
|
USAMRAA's Memo on the Animal Care and Use Review Office (ACURO) |
Memorandum for customers of the Animal Care and Use Review Office (ACURO) on guidance during the COVID-19 pandemic. |
|
Human Research Proection Office (HRPO) FAQs on COVID-19's impact to human subjects research . |
|
|
UNITED STATES DEPARTMENT OF AGRICULTURE |
|
|
National Institue of Food and Agriculture extensions due to COVID-19. |
|
| Link to USDA website for FAQs for grantees. | |
|
ADDITIONAL RESOURCES |
|
|
List of public media stations delivering educational content to families at home. |
|
|
Council on Government Relations (COGR) frequently asked questions regarding COVID-19's impact on federal awards (Version 1.1). |
|
|
Exchange visitor program information on Coronavirus |
|
|
FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic |
|
|
FDA Guidance on 3D printing of medical devices, accessories, components, and parts during the COVID-19 pandemic |
|
|
The Office of Laboratory Animal Welfare (OLAW) maintains a list of resources and has a list of FAQs, click on G9 to read about how to prepare for a pandemic. |
|
|
PCORI Guidance Related to Impact of COVID-19 |
Description: PCORI recognizes that management of COVID-19 is a rapidly evolving and dynamic situation that may impact PCORI-funded awards. If you are encountering institutional or personal challenges or have other concerns related to your PCORI award, please reach out as soon as possible to your PCORI project team: Program Officer, Program Associate, and Contract Administrator. You may also reach us at fundedpfa@pcori.org. |
|
Up-to-date information from the University of Louisiana at Lafayette. |
|
|
Information and guidance from the World Health Organization regarding the current outbreak of Coronavirus Disease (COVID-19). |
|
| LDH COVID-19 Information |
Up-to-date information from the Louisiana Department of Health. |